Stanford researchers have discovered BRP3, a novel peptide derived from the BRINP3 protein, which effectively reduces food intake and body fat in mice, while preserving muscle mass, thus offering a novel, safe and effective solution to treat obesity.
Stanford researchers have developed a high-affinity IL-11 decoy cytokine for super-agonism and antagonism of the IL-11 receptor, enabling the treatment of a wide variety of diseases from inflammatory disease to cancer as well as research into IL-11 signaling pathways.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Aging is one of the leading causes that is associated with brain dysfunction, degeneration, and disease. Progressive inflammation in the brain due to age adversely affects brain function and increases susceptibility to neurodegenerative diseases like Alzheimer's disease.
Researchers at Stanford and the University of Helsinki discovered that a human secretoglobin protein found in sweat gland cells acts as a novel host defense mechanism against Lyme disease.
Stanford scientists in Chris Garcia's lab have developed leptin analogs that have potentially more favorable pharmacokinetic and pharmacological signaling properties for use as diabetes and obesity drugs.
A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Stanford inventors have found that Stanniocalcin 2 (STC2) treatment following stoke leads to improved functional recovery and a pharmaceutical composition containing STC2 as an active ingredient can be used to facilitate post stroke recovery.
Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).